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Abstract
Background: Rheumatoid arthritis (RA) is an autoimmune disease associated with chronic inflammatory arthritis. TNF-α
and OSM are pro-inflammatory cytokines that play a key role in RA progression. Thus, reducing the effects of both
cytokines is practical in order to relieve the progression of the disease. This current study is interested in sesamin, an
active compound in sesame seeds. Sesamin has been shown to be a chondroprotective agent in osteoarthritis models.
Here, we have evaluated a porcine cartilage explant as a cartilage degradation model related to RA induced by TNF-α
and/or OSM in order to investigate the effects of sesamin on TNF-α and OSM in the cartilage degradation model.
Methods: A porcine cartilage explant was induced with a combination of TNF-α and OSM (test group) or IL-1β and
OSM (control group) followed by a co-treatment of sesamin over a long-term period (35 days). After which, the tested
explants were analyzed for indications of both the remaining and the degradation aspects using glycosaminoglycan
and collagen as an indicator.
Results: The combination of TNF-α and OSM promoted cartilage degradation more than either TNF-α or OSM alone
and was comparable with the combination of IL-1β and OSM. Sesamin could be offering protection against cartilage
degradation by reducing GAGs and collagen turnover in the generated model.
Conclusions: Sesamin might be a promising agent as an alternative treatment for RA patients. Furthermore, the
generated model revealed itself to be an impressive test model for the analysis of phytochemical substances against
the cartilage degradation model for RA. The model could be used to test for the prevention of cartilage degradation
in other biological agents induced with TNF-α and OSM as well.
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Background
Rheumatoid arthritis (RA) is a systemic autoimmune
disease associated with chronic inflammation of the syn-
ovial membrane (synovitis) and cartilage destruction of
the affected joints [1]. The progression of RA is primar-
ily associated with synovitis caused by a persistent im-
mune response from the accumulation of many immune
cells [2]. Consequently, the site is surrounded by a large
amount of cytokines and chemokines that are produced
from immune cells and inflamed synovial fibroblasts.
The major pro-inflammatory cytokines found in the syn-
ovial fluid of RA patients are Tumor necrosis factor-
alpha (TNF-α) and Oncostatin M (OSM) [3]. Previous
studies have revealed that the elevation of TNF-α and
OSM levels are implicated in the up-regulation of matrix
metalloproteinase enzymes such as the MMPs and
ADAMTs families in the chondrocyte cells. For instance,
the degrading enzymes implicated in RA are MMP1,
MMP3, MMP9, MMP13, ADAMTS4 and ADAMTS5
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[4, 5]. Thus, these active enzymes are the actual cause
of progressive cartilage destruction [4–6].
TNF-α is a cytokine that has the potential function of
stimulating many cell types [7]. It is produced primarily
by monocyte and macrophage cells, but it is also synthe-
sized by B cells, T cells and fibroblasts [7]. The main
function of TNF-α is to promote inflammation. It can
act as a potent paracrine molecule by inducing other
pro-inflammatory cytokine products such as interleukin-
1β (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8) and
granulocyte-monocyte colony-stimulating factor (GM-
CSF) [8–10]. In particular, increased amounts of these
pro-inflammatory cytokine products in RA joints pro-
mote the up-regulation of degrading enzymes at the
site of inflammation. The most potent enhancer of TNF-α
in RA progression is the IL-6 family [4, 5].
Oncostatin M (OSM) is a pleiotropic cytokine that is
produced by activated T-cells and macrophages [5]. Its
structure and function are similar to the IL-6 family.
This cytokine has been reported to contribute to joint
inflammation in RA patients [11]. It is also known to
modulate extracellular matrix turnover by controlling
the balance between MMPs and the inhibitor (TIMP) at
the damage site [12]. OSM also induces ADAMTS en-
zyme production in chondrocyte cells [6]. Additionally,
OSM can act as an enhancer for IL-1β, TNF-α and
interleukin-17 (IL-17) in the progression of cartilage
destruction by promoting the production of degrading
enzymes [5, 13].
Powerful tools are used to study the role of cytokines
in inducing cartilage degradation, these include: in vitro
models such as the monolayer culture model and the 3D
culture model, in vivo models such as the animal model
and ex vivo models such as the cartilage explant model
[5, 14–16]. However, each model has its own limitations.
For example, the monolayer culture model cannot
explain the overall progression of the disease and the 3D
culture model is suitable for anabolic study rather than a
study on catabolic function [17]. The animal model
seems to be the best model to study the progression of
the disease and for drug development. Nevertheless,
animal experiments have a serious limitation due to the
differences in biological responses; this is due to the
differences between species. Furthermore, the model is
made even more difficult because of the complicated
biological systems involved as revealed in in vivo studies
[18, 19]. In order to avoid such systemic and environ-
mental complications in the animal model, the cartilage
explant culture model has been used. It is considered
the most effective choice due to its ability to closely
represent the physiological situation, while at the same
time, it downplays any unexpected biological responses
outside of the condition of interest found in in vivo
studies [19].
Sesamin is a major lignan found in Sesamum indicum
Linn. Seed [20]. It has been reported as having the
properties needed to act as an anti-oxidant and anti-
inflammatory compound in rat models [21]. Other evi-
dence points to sesamin having the ability to inhibit
lipopolysaccharide (LPS)-induced inflammation by sup-
pressing the p38 mitogen-activated protein kinase (p38
MAPK) and nuclear factor-kB (NF-kB), which are the
main pathways that regulate cytokine production [22].
Interestingly, sesamin has also demonstrated the fact
that it is a chondroprotective agent [23]. Sesamin has
shown the ability to protect against cartilage destruction
in IL-1β-induced inflammation in the Osteoarthritis
(OA) model, both in in vitro and in vivo studies [23].
Based on this evidence, it is also possible that sesamin
could protect against cartilage degradation in other joint
diseases such as rheumatoid arthritis.
The purpose of this study was to evaluate a porcine cartil-
age explant as a cartilage degradation model induced by
TNF-α and/or OSM and to investigate the effects of sesamin
on TNF-α and OSM in the porcine cartilage explant model.
Methods
Chemicals
Chemicals and supplements were obtained from the
following suppliers: cell culture supplements such as
Dulbecco’s Modified Eagle’s Medium (DMEM), Penicillin-
Streptomycin and 0.25 % Trypsin EDTA were purchased
from Life Technologies (Burlington, Ontario, Canada).
Recombinant Human TNF-α was purchased from Pepro-
tech (Rocky Hill, USA). Human recombinant Oncostatin
M (OSM) was obtained from R&D Systems (Minneapolis,
MN). Sesamin was extracted from sesame seeds (Sesamum
indicum Linn.) and analyzed for its chemical structure by
NMR/MS (MW 354.35). Silica gel column chromatog-
raphy was purchased from Merck Millipore (Merck KGaA,
Darmstadt, Germany). Hypersil Column chromatography
for high performance liquid chromatography: Hypersil
ODS- 25, 250 4.6 mm was purchased from Thermo
electron corporation. Sesamin standard was obtained from
Sigma Aldrich (Saint Louis, Missouri, USA). Dexametha-
sone was obtained from Sigma Aldrich (Saint Louis,
Missouri, USA). Papain was purchased from Sigma Aldrich
(Saint Louis, Missouri, USA). β- nicotinamide adenine di-
nucleotide reduced disodium (β-DPNH) was purchased
from Sigma Aldrich (Saint Louis, Missouri, USA). Rabbit
anti-human ADAMTS4 antibody and mouse anti-human
MMP13 antibody were obtained from Merck Millipore
(Merck KGaA, Darmstadt, Germany). Goat anti-rabbit IgG
conjugated HRP and horse anti-mouse IgG conjugated HRP
were obtained from Cell Signaling Technology (Danvers,
MA, USA). Bradford reagent was obtained from Bio-rad
(Bio-Rad Laboratories (Singapore) Pte. Ltd.). Nitrocellulose
membranes were purchased from Amersham (Hybond-C
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Super; Amersham Pharmacia Biotech). Semi-dry blot ma-
chine was purchased from Bio-rad (Bio-Rad Laboratories
(Singapore) Pte. Ltd.). SuperSignal West Femto Maximum
Sensitivity Substrate kit was purchased from Thermo Scien-
cetific (Thermo Fisher, Lifetechnologies). Gel Documentary
system was purchased from Biorad (Bio-Rad Laboratories
(Singapore) Pte. Ltd.). Mouse Anti-human type ΙΙ collagen
antibodies were purchased from Abcam (Cambridge, United
Kingdom). Anti-mouse antibodies conjugated with HRP
were obtained from Sigma Aldrich (Saint Louis, Missouri,
USA). DAB reagent was purchased from Invitrogen
(Thermo Fisher Scientific, Waltham, Massachusetts, USA).
Cartilage explant preparation [24]
For the porcine cartilage explant model, metacarpo- and
metatarso-phalangeal joints from pigs provided by a local
slaughterhouse were dissected for articular cartilage. Cartil-
age discs (approximately 3 mm2) were randomly selected.
Selected cartilage discs or explants (3 pieces per well,
approximately 30 to 35 mg total) were cultured in a 24-well
tissue culture plate with media without FCS (DMEM) con-
taining 200 units/ml penicillin, 200 mg/ml streptomycin and
50 μg/ml gentamicin. The explants were maintained in a
humidified incubator with 5 % CO2 at 37 °C overnight for
sterility testing. After the sterility tests were done, the
explants were maintained in a serum-free media (DMEM)
for 24 h prior to the first day of treatment (this counts as
day 0 for the media). Cultured media were collected on day
7 of the culture and replaced with the same treatment every
seven days of the culture until the experiment ended
(on day 14 or 35). The explant cultured media were
stored at −20 °C until they were analyzed for indications
of degradation.
Sesamin extraction
Sesamin was prepared according to Phitak’s report [23].
Sesame seeds were amassed from Lampang, Thailand. Vou-
cher specimens were acquired (BKF No. 138181) from the
National Park, Wildlife and Plant Conservation Depart-
ment, Ministry of Natural Resources and Environment,
Bangkok, Thailand. For extraction, fine, air-dried powder
from the sesame seeds was permeated 6 times with 4 liters
of hexane for 3 days at room temperature. The liquid solu-
tion from the extraction was separated and dried under
reducing pressure conditions to afford a crude hexane
extract. Silica gel column chromatography system was
used to separate the crude extract. Elution was started
using hexane, and was progressively supplemented with
ethyl acetate in hexane up to 20 % v/v. Eluent was col-
lected as a fraction, and was then inspected by thin layer
chromatography. Fractions were evaporated. Then, the
dried fraction that gave colorless crystals was returned
and separated by silica gel column. Afterward, the distinct-
ive sub-fraction was purified by crystallization with
ethanol to earn colorless needle crystals. Nuclear magnetic
resonance spectroscopy and mass spectrometry were
performed and the extract was specified as sesamin. The
purified extract was verified by comparison with a trust-
worthy standard by co-chromatography using high per-
formance liquid chromatography (Linear gradient system
compose of Acetonitrile and H2O (50:50 to 70:50 v/v) at
the flow rate of 1.0 ml/min. Eluent was investigated at a
wavelength of 280 nm. The purified sesamin used in this
study was confirmed for its structure by NMR/MS and it
was found to be identical to trustworthy sesamin sources
(Sigma Aldrich) by HPLC.
Cartilage treatment [25]
Porcine cartilage explants were treated with various con-
centrations of sesamin in the presence of 20 ng/ml
recombinant human IL-1β and 25 ng/ml recombinant
human Oncostatin M (OSM) (control model) or 25 ng/
ml recombinant human TNF-α and 25 ng/ml recombin-
ant human OSM (tested model). Therapeutic control (25
nM Dexamethasone) was used in the test model only.
The untreated cartilage explants were used as the control
group. Throughout the 35 days of incubation, the media
were collected and replaced every 7 days of cultivation.
Cultured media were collected in order to analyze cartil-
age matrix molecules (S-GAGs and collagen release) and
catabolic enzyme (ADAMTS4 and MMP13 release)
induction. After 5 weeks of incubation, cartilage tissues
were collected and digested with 2 units/ml papain at
60 °C, and then an assay was performed for any remaining
uronic acid and collagen.
Cytotoxicity test
The toxicity of all treatments against cells in the explant
was determined by a colorimetric assay, based on the
measurement of lactate dehydrogenase (LDH) activity in
the culture media. The culture media from the cartilage
explants treated with 30 mM H2O2 were used as a posi-
tive control. The cytotoxicity of each treatment against
cartilage was assayed after treatment of the explants for
7, 14, 21, 28, and 35 days. The experiment was processed
using Berger-Broida protocol. The reaction consisted of
375 μl of 2 mM pyruvate substrate, 625 μl of 0.3 mM
β-nicotinamide adenine dinucleotide reduced disodium
(β-DPNH) in phosphate buffer solution (50 mM of
NaHPO4 and 8 mM of KH2PO4, pH 7.4), and 100 μl of
the sample was incubated at 37 °C for 30 min. After that,
1 ml of the color reagent (2, 4-dinitrophenylhydrazine in
1 N HCl) was added and was allowed to stand at room
temperature for 20 min. Stop solution (0.4 N NaOH) was
added and the absorbance of the developing color (brown
color) was measured at 450 nm. The value of the LDH
released was calculated from a standard curve.
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Determination of sulfated-proteoglycans (S-GAGs) released
in culture media
Sulfated GAGs (S-GAGs) released in media were identi-
fied using a dimethylmethylene blue (DMMB) assay
[26]. This process was performed in both the cultured
media samples and in the standard (Chondroitin 6-
sulfate (CS-C)). The DMMB solution was added to the di-
luted samples, standard and blank solution (200 μl: 50 μl)
prior to measuring absorbance at 620 nm. The value of
the S-GAGs released was calculated from a standard
curve.
The percentage of the S-GAGs released from the car-
tilage explants that were induced with TNF-α and OSM
was calculated as follows:
%change ¼
ðvalue from D7 or D14 or D21 or D28 or
D35 medium−value from D0 mediumÞ
value from D0 medium
x 100
Uronic acid (UA) assay for GAGs remaining in cartilage
The uronic acid levels remaining in the explants were
measured after papain digestion of the cartilage discs.
Measurements were taken using m-hydroxydiphenyl in a
colorimetric assay [27]. Glucuronic acid lactone was
used as the standard. Concentrated sulfuric acid-borate
reagent (300 μl) was then added to both the standard
and the samples. The reactions were incubated at 100 °C
for 15 min and then cooled down on ice. The carbazole so-
lution (50 mg carbazole in 40 ml EtOH) (12.5 μl) was
added and the reactions were incubated at 100 °C for
15 min. After that, the uronic acid reaction was cooled
down on ice. The absorbance of the pink color was de-
tected using a spectrophotometer at 540 nm.
Measurement of hydroxyproline released in media and
remaining in cartilage [28]
The hydroxyproline in the samples was oxidized into
a pyrrole with chloramin T at pH 6. At this inter-
mediate stage, samples were dyed pink using 4-
dimethylaminobenzaldehyde. Papain-digested cartilage
and cultured media were hydrolyzed with 6 N HCl at 110°
C for 24 h. After hydrolyzation, samples were freeze-dried
and resolubilized with distilled water. The diluents solu-
tion (67 % propan-2-ol) and oxidant solution (50 mM
chloramine T) were added to the samples, followed by a
color reagent of 7.5 % dimethylaminobenzaldehyde in
propan-2-ol. The reaction occurred at 60 °C for 45 min.
An absorbance of peach color was measured at 540 nm.
The percentage of collagen released from the cartilage
explants that were induced with TNF-α and OSM was
calculated as follows:
%change ¼
ðvalue from D7 or D14 or D21 or D28 or
D35 medium−value from D0 mediumÞ
value from D0 medium
x 100
Investigation of ADAMTS4 and MMP13 released in culture
medium by Western blot analysis
The culture medium from cartilage explant D7, D14,
D21, D28, and D35 were determined the protein con-
centration by using Bradford protein assay and pro-
tein concentration was calculated to produce equal
amounts before loading in SDS-PAGE (13 % separating
gel, 5 % stacking gel). The samples were separated electro-
phoretically and transferred to nitrocellulose membrane
by semi-dry blot method. After blotting, membranes were
blocked with 3 % (W/V) BSA in Tris-buffered saline with
0.1 % Tween 20 (TBS-T) for 1 h, at room temperature.
After which, the membranes were washed with TBS-T
prior to being incubated with primary antibody against
anti-ADAMTS4 or anti-MMP13 antibody (1:500 for
anti-ADAMTS4 and 1:1000 for anti MMP13 in TBS-T)
overnight at 4 °C. After that, membranes were washed 5
times for 5 min with TBT-T prior to being incubated
with the secondary antibody conjugated with horse-
radish peroxidase (1:1000 in TBS-T, anti-rabbit IgG
for anti ADAMTS4 and anti-mouse IgG antibody for
anti-MMP13) for 1 h at room temperature. Blots
were washed 5 times for 5 min with TBS-T before be-
ing visualized using SuperSignal West Femto Maximum
Sensitivity Substrate kit for enhanced chemiluminescence.
The visualized results were taken using the Gel Documen-
tary system.
Safranin O staining
The sections were stained with safranin O to determine
the amount of S-GAGs remaining in the cartilage [29].
The sections were deparaffinized using xylene and were
then dehydrated using 95 % ethanol and absolute etha-
nol, respectively. The dehydrated sections were stained
with safranin O for 30 min. After that, the stained sec-
tions were rehydrated and mounted.
Immumohistochemistry for type II collagen
For the immunohistological analysis of the remaining type
II collagen [30], after deparaffinization and rehydration, the
sections were first digested with 0.25 % trypsin, then,
1.45 IU/ml testicular hyaluronidase and finally, 0.25 IU/ml
chondroitinase ABC for 15 min at 37 °C for each step.
Consequently, endogenous peroxidase was blocked in the
sections using 3 % H2O2 in PBS and non-specific sites were
blocked with 3 % BSA in PBS. Sections were incubated
with mouse monoclonal anti- type II collagen (1:100) for
24 h at 4 °C. Following that, the anti-mouse polyvalent
immunoglobulin conjugate HRP (1:25) was incubated for
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1 h at room temperature. After being washed with PBS,
the sections were color-stained using peroxidase sub-
strate (DAB reagent set), followed by rehydration. The
sections were mounted with a mounting medium and left
at room temperature until they were dried.
Statistics analyses
The significance of the differences between the groups
of data was assessed using One-way ANOVA, SPSS and
all groups were expressed as mean ± SD. Statistical
significance was assumed at P < 0.05.
Results
TNF-α combined with OSM promoted a high degree of
cartilage degradation in the porcine cartilage explant
model
To assess the strength of pro-inflammatory cytokines on
cartilage degradation, the explants were stimulated with
TNF-α or OSM alone or a combination of TNF-α and
OSM at concentrations of 6.25, 12.5, and 25 ng/ml for
14 days. The cultured media were collected every 7 days
and replaced with the same conditional treatment. After
the experiment ended, the explants were harvested. The
cultured media that were collected on day 7 and day 14
of the culture were inspected to determine S-GAGs
levels, while the explants were checked for remaining
amounts of uronic acid. After the 14-day period, it was
shown that the presence of TNF-α or OSM alone in the
porcine cartilage explant culture induced a low level of
proteoglycan depletion in a dose-dependent manner
(Fig. 1). TNF-α or OSM alone at 25 ng/ml induced S-
GAGs release at about 113 and 115 % when normalized
with the control (control = 100 %), respectively (Fig.1a).
However, a combination of both cytokines increased S-
GAGs release to about 134 % (Fig. 1a). Moreover, it
was shown in the levels of remaining uronic acid that
OSM had a synergistic effect with TNF-α (Fig. 1b). The
combination of 25 ng/ml TNF-α and OSM exhibited
the highest level of the cartilage degradation marker.
This concentration was chosen selected for use in fur-
ther experiments.
TNF-α and OSM induced S-GAGs degradation that was
comparable with IL-1β and OSM induction, and sesamin
showed protective effects on S-GAGs degradation with
TNF-α and OSM
Firstly, to evaluate the cytotoxicity of all conditions, the
culture media from all conditions or H2O2 treatment
condition were used to test LDH activity. The toxic con-
trol showed increased levels of LDH released in the
media, while TNF-α, OSM, IL-1β or its combination and
sesamin treatment did not appear to affect the amount
of LDH released in the cultured media (Fig. 2a). Some
treatments showed slightly increased levels of released
LDH (Fig. 2). However, these released LDH levels did
not reach toxic levels when compared with the toxic
control (Fig. 2). The results indicated a nontoxicity of all
treatments on chondrocyte cells.
The determination of S-GAGs degradation represented
the different pattern of single-cytokine treatment and co-
cytokine treatment in the porcine cartilage explant model.
In IL-1β, TNF-α, and OSM alone treatment conditions, S-
GAGs were continuously depleted, meanwhile both combi-
nations of cytokine treatment conditions showed short and
strong effects (Fig. 3a). The combination of TNF-α and
OSM at a concentration of 25 ng/ml enhanced the deple-
tion of GAGs in the porcine cartilage culture when com-
pared with the TNF-α or OSM treatment alone (Fig. 3a).
However, S-GAGs damaged from the combination of
TNF-α and OSM condition was still lesser than the
Fig. 1 Significant S-GAGs depletion and uronic acid remaining in
cartilage when induced with TNF-α/OSM alone or TNF-α in
combination with OSM. The levels of S-GAGs released in the media
were assayed as described in the Methods section. a S-GAGs released
in the media represented as the percentage of accumulation of
S-GAGs that were released at 7 days and 14 days. b Percentage of
uronic acid retained in the cartilage after treatment ended (14 days).
Values are presented as mean ± SD (n = 3). * = p < 0.05; ** = p < 0.01
versus normal control. Data represents 3 separate cartilage samples
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combination of IL-1β and OSM treatment (Fig. 3a). The
highest level of S-GAGs released was detected in the sec-
ond week of treatment and decreased by the next week. In
accordance with previous reports, co-treatment with sesa-
min at a concentration of 10 μM exhibited a significantly
lower percentage of the accumulation of S-GAGs released
when compared with the IL-1β and OSM co-treatment
groups (Fig. 3a). Interestingly, TNF-α and OSM co-
treatment with sesamin at concentration 0.1 μM also de-
creased the percentage of S-GAGs released when compared
with the cytokines-induced group. However, co-treatment
with sesamin at a concentration of 10 μM showed a higher
percentage of S-GAGs released (Fig. 3b). The dexametha-
sone co-treatment, which is currently used as a therapeutic
drug, induced a higher percentage of the S-GAGs released
in the second week of treatment when compared with the
TNF-α and OSM co-treatment groups (Fig. 3b).
Almost all cytokine treatment conditions resulted in a
reduction of uronic acid remaining in the cartilage except
for the TNF-α alone condition (Fig. 3c). Similarly to the S-
GAGs released results, the combination treatment of
TNF-α and OSM could reduce the percentage of uronic
acid remaining at the same level as the co-treatment of
IL-1β and OSM (Fig. 3c). Sesamin was able to slightly re-
tain uronic acid remaining in the cartilage under the
stimulating condition that was likely expressed in the
dexamethasone treatment (Fig. 3b, d).
TNF-α and OSM induced collagen degradation and
sesamin showed protective effect against these cytokines
The change of collagen in the cartilage was investigated
for both its degrading and remaining aspects. The
degradation of collagen was determined by measuring
its release in the culture medium, and the remaining
aspect was studied by quantifying the amount of colla-
gen existing in the explant after the culture period had
ended. As expected, the level of collagen released from
cartilage was detected at high levels near the end of the
experiment’s duration (Fig. 4a, b). From these results,
elevated collagen degradation levels were shown in the
cartilage, which was cultured under the induced condi-
tion (Fig. 4a). Therefore, co-treatment of TNF-α and
OSM significantly induced high levels of collagen
depletion, while the induction level was lower than that
which was induced by OSM alone (Fig. 4a). While IL-
1β combination with OSM showed a slight increase in
the amount of collagen released in the culture media
(Fig. 4a). A co-treatment with sesamin relieved those
effects in both the TNF-α/OSM and IL-1β/OSM in-
duced conditions (Fig. 4a, b). A significant reduction
in the percentage of collagen released in the medium
was found when sesamin was introduced at a concen-
tration of 10 μM (Fig. 4b). Additionally, the collagen
remaining in the cartilage produced harmonious re-
sults; the collagen remaining in the explants decreased
when stimulated with pro-inflammatory cytokines,
while in the presence of the sesamin treatment, sesa-
min proved to lighten the unwanted effects (Fig. 4c, d).
The sesamin treatment’s results were comparable to
those of the dexamethasone treatment (Fig. 4b, d).
TNF-α and OSM induced the releasing of ADAMTS4 and
MMP13 that was comparable to IL-1β and OSM induction
The matrix metalloproteinase enzymes that were involved
in aggrecan and collagen degradation were also observed.
In this experiment, ADAMTS4 and MMP13 expression
levels were determined in all conditioned media. From
these results, both IL-1β and TNF-α alone treatments
induced matrix metalloproteinase enzymes released while
OSM treatment alone revealed only slight effects (Fig. 5).
The combination cytokines system showed a stronger in-
duction level when compared to the single-cytokine
system. Moreover, TNF-α and OSM induced ADAMTS4
Fig. 2 The release of LDH in the culture media. The amount of LDH released in the culture medium was determined as described in the research
methodology. a. Percentage of LDH released in the media from the cytokine(s)-induced condition normalized against the percentage of LDH
released from H2O2 treatment. b. Percentage of LDH released in the media from a combination of TNF-α and OSM induced-condition with
sesamin normalized against the percentage of LDH released from the H2O2 treatment. Values are presented as mean ± SD (n = 3). Data represents
3 separate cartilage samples
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and MMP13 were released at the same levels as the IL-1β
in combination with OSM. In the IL-1β and OSM treat-
ment, 10 μM of sesamin could not inhibit the cytokine ef-
fect in terms of both ADAMTS4 and MMP13 expression.
However, sesamin demonstrated the slightly reduced ef-
fects on both ADAMTS4 and MMP13 production in the
TNF-α and OSM condition (Fig. 5).
TNF-α combination with OSM demonstrated severe cartilage
degradation and sesamin could protect GAGs and collagen
depletion from cartilage induced with TNF-α and OSM
The important evidence that supported the chondroprotec-
tive effects of sesamin against TNF-α/OSM-induced cartil-
age degradation came from a histological examination
(Fig. 6a). TNF-α/OSM and IL-1β/OSM caused severe car-
tilage damage when compared with other conditions, which
was observed due to the cartilage’s abnormal appearance
(Fig. 6a). Additionally, the chondrocytes seemed unhealthy
when compared with the normal specimens in the control
group. Moreover, the surface of the cartilage explants when
under the induced condition seemed decomposed. How-
ever, the presence of sesamin in the induction system re-
sulted in better chondrocyte cell morphology and a healthy
appearance of the cartilage, which was similar to results
found in the dexamethasone treatment (Fig. 6b). Further-
more, the results clearly indicated that the induction with
TNF-α in combination with OSM caused a severe loss of
S-GAGs in the cartilage as same as IL-1β and OSM. The
presence of sesamin could protect S-GAGs from depletion
in both combinations of cytokine-induced cartilage. Al-
though, in the TNF-α/OSM treatment, the lower concen-
tration value of sesamin seemed to maintain S-GAGs more
Fig. 3 The percentage accumulation of S-GAGs released in the culture media and the percentage of uronic acid remaining in the cartilage
explants versus the normal control. a, b The percentage of S-GAGs released that was accumulated and normalized against the percentage of
S-GAGs released on day 0. c, d The percentage of uronic acid remaining in the cartilage after the end of the experiment. Values are presented as
mean ± SD (n = 3). #, @, * = p < 0.05; ##, @@, ** = p < 0.01 versus control (#) or the combination of IL-1β and OSM treatment (@) or the combination of
TNF-α and OSM treatment (*). Data represents 3 separate explant samples
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Fig. 4 The percentage of collagen released in accumulation in the media and the percentage of collagen that remained in the cartilage explants
under different conditions. The amount of collagen released in the media and the amount of collagen remaining in the digested cartilage were
determined as described in the Methods section. a, b The change in percentage of collagen released that was accumulated in the media under
various conditions and normalized against the percentage of collagen released on day 0. c, d The percentage of collagen that remained in the
cartilage explants after the end of the experiment. Values are presented as mean ± SD (n = 3). #, * = p < 0.05; ##, ** = p < 0.01 versus control (#) or
versus the combination of TNF-α and OSM treatment (*). Data represents 3 separate explant samples
Fig. 5 Western Blotting results for mornitoring the changes of ADAMTS4 and MMP13. The releasing of ADAMTS4 and MMP13 in the media were
investigated as described in the Methods section. a The change in ADAMTS4 released in the media. b The change in MMP13 released in the
media. The number above each band indicates band density (total density = active form + proform)
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effectively than was found with the higher concentration
value of sesamin (Fig. 6b). For type ΙΙ collagen content, the
long-term induction of cartilage with TNF-α and OSM
caused a severe loss of collagen (Fig. 6). Notably, collagen
that was co-cultured with sesamin was protected from de-
pletion when sesamin was introduced in a dose-dependent
manner (Fig. 6b). However, the protective effects of sesamin
were shown to be less than those of the dexamethasone
treatment.
Discussion
Rheumatoid arthritis (RA) is a chronic systemic auto-
immune disease. It is characterized by chronic inflamma-
tion of the synovial membrane (synovitis) and progressive
cartilage damage [1]. The progression of RA is primarily
associated with synovitis caused by a persistent immune
response from the accumulation of many immune cells
[2]. Consequently, the site is surrounded by a large
amount of cytokines, chemokines and proteolytic en-
zymes, which affect the cartilage and bone structure [2].
Cartilage destruction in RA is caused by a loss of extracel-
lular matrix such as proteoglycans and collagen that are
controlled by matrix metalloproteinase enzymes (MMPs)
and a disintegrin and metalloproteinase with thrombos-
pondin motifs (ADAMTS) synthesized from chondrocyte
cells [4, 5]. These enzymes are up-regulated by a variety of
cytokines, especially TNF-α and OSM that emerge during
an inflammatory event [7]. These cytokines are also
known as pro-inflammatory cytokines and are closely in-
volved in RA [3]. In this study, the cartilage explant model
was used to observe cartilage degradation. Even though
the cartilage explant model presents numerous benefits,
this method also has its own limitations [31]. Some limita-
tions of the cartilage explant model could not be avoided.
When employing this method, the amount of chondrocyte
cells in the explant in each treatment could not be con-
trolled, even when utilizing measurement by weight. The
cutting of the cartilage also causes the chondrocyte cells
to die. In order to meet the demand for the experiment,
cartilage samples were obtained from various sources. It is
quite difficult to control the response from individual
samples. However, this model more closely represents the
physiological environment than does the monolayer culture
model and this model minimizes the presence of the
complicated systems found in the animal model study
[18, 19]. The experiment of this study was designed
to mimic the microenvironment surrounding the inflam-
matory joint found in RA. The designed experiment was
also investigated compared with IL-1β and OSM, which is
a well-known inducer for the cartilage explant model.
Throughout the experiment, the changes in the samples’
proteoglycans (GAGs), collagen, aggrecanase (ADAMTS4),
Fig. 6 Histology staining; H&E staining for chondrocyte cell morphology, Safranin O staining for S-GAGs in cartilage (red color) and
immunohistochemistry staining for type ΙΙ collagen remaining in the cartilage (brown color) (x400). a Histology staining of cytokine(s)-induced
conditions. b Histology staining of co-treatment of TNF-α and OSM induced-condition with sesamin
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and collagenase (MMP13) were monitored. The break-
down of S-GAGs and collagen from the cartilage is an ap-
proved method of marking cartilage degradation. S-GAGs
and collagen depletion leads to a malfunction of the extra-
cellular matrix and generates cartilage dysfunction [32, 33].
It is believed that the loss of GAGs, especially aggrecan, is
the primary step in the process of cartilage destruction
[33]. In this study, the depletion of S-GAGs was investi-
gated by monitoring the levels of S-GAGs released in the
media. This is a sign of the degeneration of the damaged
cartilage. Uronic acid remaining in the cartilage was also
observed, as this is related to the number of remaining
GAGs. Moreover, changes in the collagen were monitored
by observation of the collagen that was released in the cul-
tured media. The release of collagen indicates the presence
of severely damaged cartilage because the loss of the fibril-
lar structure is a cause of irreversible tissue destruction
[34]. The collagen remaining in the explants is considered
to be retained collagen. Furthermore, representative of the
matrix metalloproteinases enzymes, namely ADAMTS4
and MMP13, which function as aggrecanase and collage-
nase, respectively, were also investigated. Both enzyme pro-
duction levels reveal the role of cytokine-induced cartilage
damage [6, 35]. A histological staining was performed in
order to confirm the amounts of S-GAGs and collagen
retained.
In this study, it was found that only IL-1β or TNF-α
or OSM-treated cartilage explants caused a slight deple-
tion of S-GAGs (an amount harmonious with the level
of uronic acid remaining in the explants). In addition,
TNF-α combined with OSM was found to have additive
effects when used as a treatment in the cartilage ex-
plants. These results were in accordance to those of the
co-treatment of IL-1β and OSM. The results suggest
that the combined TNF-α and OSM treatment is appro-
priate for use in the cartilage explant model for the
study of cartilage degradation. In fact, the combination
treatment is closer to the actual pathogenic situation
than the single-cytokine systems. This study has shown
that long-term exposure of TNF-α and OSM around the
porcine cartilage explant model can cause severe cartilage
damage. From these results, it has been demonstrated that
S-GAGs depletion occurs in the early stages of degrad-
ation, while the breakdown of collagen occurs in the late
stages. S-GAGs depletion was definitely detected during
the second week of cytokine induction and it continued to
be present until the end of the experiment (the fifth week).
This suggests that S-GAGs breakdown can be used as an
early biomarker of cartilage destruction.
As for collagen depletion, only IL-1β or TNF-α treated
cartilage explant produced a harmless effect to collagen,
whereas only the OSM treated cartilage explant showed
a highly degraded level of collagen. There is no other
evidence to support the depletion of collagen from the
treatment with OSM alone. However, in the actual situ-
ation, the rheumatic joint is surrounded by many cyto-
kines. For this reason, the combined cytokine system is
more similar to the pathophysiology of the disease than
the single-cytokine system. Therefore, this study has
proven that cartilage damage that is induced by a combin-
ation of TNF-α and OSM leads to significant collagen
breakdown (this occurred in the later periods of the ex-
periment), whereas a combination of IL-1β and OSM had
a lighter effect on collagen degradation. Thus, the TNF-α
and OSM co-treatment model is suitable for the study of
a cytokine induced cartilage degradation disease, as IL-1β
combined with OSM. Moreover, collagen breakdown can
also be used as a marker for severe cartilage degradation.
The mechanism of cytokine induced S-GAGs and col-
lagen depletion in RA lesions is caused by the overpro-
duction of matrix metalloproteinase enzymes [3–5, 7].
ADAMTS4 and MMP13 proteins were chosen as a rep-
resentative of the enzyme group because there is a signifi-
cant amount of evidence to suggest that both enzymes are
regulated by TNF-α, IL-1β or OSM [5, 34, 36]. From these
studies, the co-cytokine treatment system gave a different
result from the single-cytokine system. IL-1β or TNF-α
treatment showed a prolonged level of induction for both
enzymes when TNF-α or IL-1β in combination with OSM
presented a short and strong level of induction. OSM
alone slightly induced the release of both ADAMTS4 and
MMP13. This result is inconsistent with the results of the
collagen released, for which OSM showed the strongest
effect. OSM might induce some other matrix metallopro-
teinase enzymes except ADAMTS4 and MMP13. TNF-α
or IL-1β combination with OSM strongly induced
ADAMTS4 and MMP13 that were released within a 2-
week period and decreased the induction by the next
week. Moreover, this inconsistency might be due to the
multi-properties of OSM. OSM has been acknowledged
for its pro- and anti-inflammatory properties [37].
Sesamin is an active compound from sesame seeds
that has been identified as an agent that has the domin-
ant property of being an anti-inflammatory substance
[20, 21]. It has also been proven to be a chondroprotec-
tive agent in the osteoarthritis model induced with IL-1β
[23]. As a consequence of a number of previous experi-
ments, this study tested the properties of sesamin by in-
vestigating its ability to protect against cartilage damage.
This was achieved by using the porcine cartilage explants
induced with a combination of IL-1β or TNF-α with the
OSM model. The use of these models had demonstrated
that sesamin did show protective effects. Because of the
presence of sesamin, there was a reduction in the amounts
of both early (S-GAGs) and late (collagen) cartilage deg-
radation markers in the induced cartilage. The release of
S-GAGs and collagen was significantly reduced when
compared with the release found in the cytokine control
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group. The effects of sesamin were also found in the direct
measurements of both S-GAGs and collagen in the cartil-
age during a histological examination. Sesamin also
slightly reduced ADAMTS4 and MMP13 enzymes that
were released in the early stages of these models. The
greatest concentration of sesamin that was found to pro-
tect cartilage from TNF-α and OSM induction in this
study was 0.1 μM. In addition, dexamethasone, which is a
medicine currently used for the treatment of cartilage deg-
radation, was included in this investigation. Previously,
dexamethasone has been extensively reported on concern-
ing its ability to up-regulate Interleukin-10 (IL-10), which
is a cytokine that induces the synthesis of endogenous
TNF-α inhibitors, such as soluble TNF-α receptors. This
cytokine has also been acknowledged to down-regulate
the TNF receptor expression in immune cells [38, 39]. In
this way, dexamethasone could be used as a positive con-
trol. In the experiment, the dexamethasone treatment
clearly showed protective effects on cytokine-induced car-
tilage explants, while sesamin produced the same results
that dexamethasone did. Interestingly, the effective dose
of sesamin was found in the low concentration.
Conclusions
Again, it must be stated that this study strongly con-
firmed that the cartilage explant model induced with
TNF-α and OSM is a suitable model for the study of the
effects of cartilage-protective substances. While using
this appropriate model, it was found that sesamin, which
is a natural substance extracted from sesame seeds, has
clear chondroprotective effects. Importantly, sesamin is
non-toxic to chondrocyte cells. These results suggest
that sesamin has the valuable property of being able to
relieve cartilage degradation events in a pathogenesis
caused by the elevation of TNF-α and OSM levels. An
example of such an event is RA. However, the mechan-
ism which sesamin uses against the destruction caused
by the combination of TNF-α and OSM is still unknown
and further studies should be performed in order to
identify this mechanism.
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